PMC6480678_01
PMC6480678_02
PMC6480678_03
Clinical courses of case 1 (a) and case 2 (b) during tocilizumab therapy
41927_2019_63_Fig1_HTML.jpg
PMC6480678_05_41927_2019_63_Fig1_HTML.jpg
Fig1
DMARD (cyclosporine 150 mg/day) was continued (Fig. 1b). During the 18-month period of TCZ therapy, both RA disease activity and mRSS decreased. At 18 months, the patient global assessment improved by 32 (68 to 36), RA disease activity decreased (DAS28-ESR decreased from 7.14 to 3.70; CDAI decreased from 34.6 to 8.4), and skin thickness evaluated with the mRSS improved from 15 to 7 (Fig. 1b).
PMC6480678_04
PMC6480678_05
Clinical courses of case 1 (a) and case 2 (b) during tocilizumab therapy
41927_2019_63_Fig1_HTML.jpg
PMC6480678_05_41927_2019_63_Fig1_HTML.jpg
Fig1
DMARD (cyclosporine 150 mg/day) was continued (Fig. 1b). During the 18-month period of TCZ therapy, both RA disease activity and mRSS decreased. At 18 months, the patient global assessment improved by 32 (68 to 36), RA disease activity decreased (DAS28-ESR decreased from 7.14 to 3.70; CDAI decreased from 34.6 to 8.4), and skin thickness evaluated with the mRSS improved from 15 to 7 (Fig. 1b).
PMC6480678_06